Vistagen Therapeutics (VTGN) Assets Average (2012 - 2026)

Vistagen Therapeutics has disclosed Assets Average across 12 years of filings, most recently posting $42.2 million for Q2 2026.

• In Q2 2026, Assets Average fell 45.0% year-over-year to $42.2 million; the TTM figure through Jun 2026 stood at $42.2 million (down 45.0% YoY), while the FY2026 annual figure was $66.5 million, down 36.1% from the prior year.
• Assets Average came in at $42.2 million for Q2 2026 at Vistagen Therapeutics, down from $56.8 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $127.4 million in Q1 2024 to a low of $18.1 million in Q2 2023.
• Average Assets Average over 5 years is $69.8 million, with a median of $74.0 million recorded in 2025.
• Year-over-year, Assets Average slumped 72.92% in 2023 and jumped 556.68% in 2024.
• Over 5 years, Assets Average stood at $35.2 million in 2022, then surged by 146.08% to $86.6 million in 2023, then climbed by 12.43% to $97.4 million in 2024, then dropped by 25.06% to $73.0 million in 2025, then tumbled by 42.25% to $42.2 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $42.2 million in Q2 2026, $56.8 million in Q1 2026, and $73.0 million in Q4 2025.